medigraphic.com
ISSN 1665-3254 (Print)
Revista Oficial de la Universidad Biomédica Rafael Guízar y Valencia A. C.

2007, Number 1-2

<< Back Next >>

Plasticidad y Restauración Neurológica 2007; 6 (1-2)

Recommendations for the treatment to somatic painful neuropathy for diabetes mellitus

Flores RJ, Aguilar RF

Language: Spanish
References: 32
Page: 27-34
PDF size: 186.43 Kb.


ABSTRACT

Chronic neuropathic pain is a commonly problem encountered in clinical practice. It has been estimated that here may be more than 2 million people with painful diabetic neuropathy (PDN) in Mexico and close to 3 million in the United States
A variety of agents are used for treatment, but PDN is often refractory to many therapies. PDN often results in significant morbidity and health care resource use. PDN is a common complication of diabetes that can profoundly diminish quality of life. And some estimation in Mexico established of diabetic neuropathy is 35% to 50% of diabetic’s patients suffer this complication after 10 years by diagnosis. Education, patient support, and reassurance are important components of treatment of these common and potentially debilitating disorders.


REFERENCES

  1. Duby JJ Campbell RK et al. Diabetes neuropathy an intensive review. Am J Wil S, Roglic G, Green A, Sicree R, King H. Global prevalence for the year 2000 and projections for 2030. Diabetes Care 2004:27(5):1047-1053.

  2. Barceló A, Rajpathak S. Incidence and prevalence of diabetes mellitus in the America. Pan Am J Public Heath 2001:10(5);300-308.

  3. Secretaría de Salubridad y Asistencia. Reporte de la Encuesta Nacional de Enfermedades Crónicas 1992. México: SSA; 1993:19-24.

  4. Secretaría de Salud. Morbilidad. 2000. México Secretaría de Salud: 2003:25-51.

  5. Barquera S, Tovar-Guzmán V, Campos-Nonato I, González-Villalpando C, Rivera- Dommarco J. Geography of diabetes mellitus mortality in México: An epidemilologic transition análisis. Arch Med Res 2003;34(5):407-414.

  6. Arredondo A, Zuñiga A. Economic consequences of epidemiological changes in diabetes in middle income countries: the Mexican case Diabetes Care 2004:27(1):104-109.

  7. Velásquez-Monrroy O, Rosas-Peralta M, Lara-Esqueda A, Pastelín-Hernández G, Castillo C, Attie F. Prevalencia e interrelación de enfermedades crónicas no transmisibles y factores de riesgo cardiovascular en México: resultados finales de la Encuesta Nacional de Salud (ENSA) 2000. Arch Cardiol Mex 2003;73: 62-77.

  8. Aguilar-Salinas CA, Velásquez-Monroy O, Gómez-Pérez FJ. Characteristics of patients with type 2 diabetes in Mexico: Result from a large population based nationwide survey. Diabetes Care 2003.26(7);2021-2026.

  9. Simmons Z, Feldman El. Update on diabetic neuropathy. Curr Opin Neurol 2002;15:595-603.

  10. Schmader KE. Epidemiology and impact on quality of life of post herpetic neuralgia and painful diabetic neuropathy. Clin J Pain 2002;18:350-354.

  11. Wilson JL, Sokol DK, LH et al. Acute painful neuropathy (insulin neuritis) in a boy following rapid glycemic control for type1 diabetes mellitus. J Child Neurol 2003;18:365-367.

  12. Aguilar-Rebolledo F. Neuropatía diabética. Aspectos prácticos, diagnósticos, terapéuticos y medidas profilácticas; Manifestaciones Clínicas, 2a. edición, Editorial Alfil, en prensa:123-144.

  13. Barbano R, Hart-Gouleau S, Pennella-Vaughan JD. Working Pain. Headache Rep 2003;7:169-177.

  14. Max MB, Lynch SA, Muir J et al. Effects of desipramine, amitriptyline, and fluxetine on pain in diabetic neuropathy. N Engl J Med 1992;326:1250-1256.

  15. Sindrup SH, Gram LF, Brosen K et al. The selective serotonin reuptake inhibitor paroxetine is effective in the treatment of diabetic neuropathy symptoms. Pain 1990;42:135-144.

  16. Semenchuk MR, Sherman S, Davis B. Double-blind, randomized trait trial of bupropion SR for the treatment of neuropathy pain. Neurology 2001;57:1583-1558.

  17. Eisenberg E, Luire Y, Braker C et al. Lamotrigine reduces study. Neurology 2001;57:505-509.

  18. Walson CP, Moulin D, Watt-Watson J et al. Controlled-release oxycodone relives neuropathy pain: a randomized controlled trial in painful diabetic neuropathy. Pain 2003;105:71-78.

  19. Hotta N, Totoya T, Matsuoka K et al. Clinical efficacy of fidalrestat, a novel aldose reductase inhibitor, for diabetic peripheral neuropathy: a 52-week multicenter placebo-controlled double blind parallel group study. SNK-860 Diabetic Neuropathy Study Group (published erratum appears in Diabetes Care 2002;25:413-4). Diabetes Care 2001;24:1776-1782.

  20. Harati Y, Gooch C, Swenson M et al. Double-blind random neuropathy. Neurology 1998;50:1842-1846.

  21. Kumar D, Marshall HJ. Diabetic peripheral neuropathy: amelioration of pain with transcutaneous electro stimulation. Diabetes Care 1997;20:1702-1705.

  22. The effect of intensive diabetes therapy on the development and progression of neuropathy. The Diabetes Control and Complications Trial Research Group. Ann Intern Med 1995;122:561-568.

  23. Sindryp SH, Jensen TS. Efficacy of pharmacological treatments of neuropathic pain: an update and effect related to mechanism of drug action. Pain 1999;83:389-400.

  24. FDA approves drug for neuropathic pain associated with diabetes. 7 Sep 2004 Available at www.fdagov/bbs/topics/news/2004/new01113.html.Accessed 27 Oct 2004.

  25. Aguilar-Rebolledo F. Neuropatía diabética, Trasplante de Páncreas. 2a. edición, Ed. DEMSA, 2003:408-410.

  26. Younger DS. Diabetic peripheral neuropathy. Drugs today (Barc) 1998;34(8):699-708.

  27. Ziegler D, Hanefel M, Ruhnau KJ et al. Treatment of symptomatic diabetic peripheral neuropathy with the antioxidant alpha-lipoic acid. A three-week multicentre randomized controlled trial (ALADIN study). Diabetología 1995;38:1425-1433.

  28. Reljanovic M, Reichel G, Reett K et al. Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alpha lipoic acid): a two year multicenter randomized double blind placebo-controlled trial (ALADIN II). Alpha Lipoic Acid in Diabetic Neuropathy. Free Radic Res 1999;31:171-179.

  29. Ziegler D, Hanefeld M, Ruhnau KJ, Hasche H, Lobisch M, Schutte K et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). Diabetes Care 1999;22(8):1296-1301.

  30. Ziegler D, Schatz H, Conrad F, Gries FA, Ulrich H, Reichel G. Effects of treatment with the antioxidant alpha-lipoic acid on cardiac autonomic neuropathy in NIDDM Patients: a 4-month randomized controlled multicenter trial (DEKAN study). Diabetes Care 1997;20(3):369-373.

  31. Ametov AS, Barinov A, Dyck P, Herman R, Kozlova N, Litchy WJ et al. The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid: The Sydney trial authors: The Sydney trial study group. Diabetes Care 2003;26:770-776.

  32. Zielger D, Nowak H, Low PA. Treatment of symptomatic diabetic polyneuropathy with antioxidant alpha-lipoic acid: a meta-analysis. Diabetic Medicine 2004;21:114-121.




2020     |     www.medigraphic.com